Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07374068

Prognostic Model of Elderly Hodgkin Lymphoma in China

This multicenter observational cohort study is based on a patient registry designed to systematically collect uniform real-world clinical data from elderly patients with Hodgkin lymphoma (HL) in China. The registry captures demographic characteristics, disease features, laboratory parameters, treatment patterns, and longitudinal survival outcomes to support predefined scientific objectives.

The primary analysis uses retrospectively collected registry data, with prospectively accrued data incorporated for external validation of a prognostic prediction model. This registry-based study aims to improve risk stratification and inform individualized clinical decision-making for elderly patients with HL in routine clinical practice.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Hodgkin Lymphoma Hemic and Lymphatic Diseases Hodgkin Disease Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

60 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tianjin Cancer Hospital

Tianjin, Tianjin Municipality, 300060, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥60 years
  • Histologically confirmed Hodgkin lymphoma, including classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma
  • Treatment-naïve patients who have not received prior anti-Hodgkin lymphoma therapy
  • Availability of complete clinical, pathological, and follow-up data

Exclusion criteria

  • Presence of other malignant tumors
  • Severe hepatic or renal dysfunction (Child-Pugh class C or estimated glomerular filtration rate <30 mL/min)
  • Missing more than 20% of required clinical data

Treatment and study plan

Primary outcomes

  1. Overall Survival (OS)

    Time frame: From date of diagnosis until death from any cause, assessed up to 60 months.

    Overall survival (OS) is defined as the time from diagnosis to death from any cause.

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time frame: From date of diagnosis until the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 60 months.

    Progression-free survival (PFS) is defined as the time from diagnosis to disease progression or death from any cause.

  2. Disease-Free Survival (DFS)

    Time frame: From date of first documented remission until disease relapse or death from any cause, whichever occurs first, assessed up to 60 months.

    Disease-free survival (DFS) is defined as the time from remission to disease relapse or death from any cause.

  3. Event-Free Survival (EFS)

    Time frame: From date of diagnosis until treatment failure, disease relapse, or death from any cause, whichever occurs first, assessed up to 60 months.

    Event-free survival (EFS) is defined as the time from diagnosis to treatment failure, disease relapse, or death from any cause.

  4. Proportion of Participants With Disease Progression or Death Within 24 Months From Diagnosis (POD24)

    Time frame: From date of diagnosis to 24 months after diagnosis.

    Progression of disease within 24 months (POD24) is defined as the occurrence of documented disease progression or death from any cause within 24 months from the date of diagnosis.

Sponsors and collaborators

Lead sponsor

Tianjin Medical University Cancer Institute and Hospital

Other

Registry information

Official study title

Clinical Characteristics and Prognostic Model Analysis of Elderly Patients With Hodgkin Lymphoma in China

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Jan 28, 2026
Registry last updated
Jan 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.